China Orphan Diseases Drugs Market Analysis

China Orphan Diseases Drugs Market Analysis


$ 3999

The China Orphan Diseases Drugs Market is projected to grow from $12.445 Bn in 2022 to $30.375 Bn by 2030, registering a CAGR of 11.8% during the forecast period of 2022 - 2030. Some of the most common orphan diseases in China include thalassemia, hereditary hearing loss, and primary immunodeficiency diseases. Some of the key players in the China orphan diseases drugs market include Roche, Novartis, Pfizer, Sanofi, AstraZeneca, GlaxoSmithKline, Merck, AbbVie, Johnson & Johnson, and Takeda.

ID: IN10CNPH019 CATEGORY: Pharmaceuticals GEOGRAPHY: China AUTHOR: Shivam Zalke

Buy Now

China Orphan Diseases Drugs Market Executive Summary

The China Orphan Diseases Drugs Market is projected to grow from $12.445 Bn in 2022 to $30.375 Bn by 2030, registering a CAGR of 11.8% during the forecast period of 2022 - 2030.

The China Orphan Diseases Drugs Market is growing due to increasing awareness and better access to healthcare. The government has also implemented policies to support the development of treatments for these diseases. However, high costs and limited patient populations for these drugs continue to challenge the market's growth.

Orphan diseases in China are rare and debilitating conditions that affect a small number of people. Some of the most common orphan diseases in China include thalassemia, hereditary hearing loss, and primary immunodeficiency diseases. The lack of attention and funding for research and treatment of these diseases has led to limited options for patients. However, recent efforts by the government and healthcare organizations are increasing awareness and access to care for those affected by orphan diseases in China.

china orphan disease drugs market analysis

Market Dynamics

Market Drivers

The key drivers of the China orphan diseases drugs market are:

  1. Increasing awareness: Increased public and government awareness of the burden of orphan diseases is driving demand for treatments
  2. Government support: The Chinese government has implemented policies to support the development and approval of drugs to treat orphan diseases
  3. Improving healthcare access: Improved access to healthcare and increased spending on healthcare are contributing to the growth of the market
  4. Growing patient population: The number of people affected by orphan diseases in China is increasing, driving demand for treatments
  5. Advances in technology: Advances in technology and research are leading to the development of new treatments for orphan diseases

Competitive Landscape

Key Players

Some of the key players in the China orphan diseases drugs market include:

  • Roche
  • Novartis
  • Pfizer
  • Sanofi
  • AstraZeneca
  • GlaxoSmithKline
  • Merck
  • AbbVie
  • Johnson & Johnson
  • Takeda

These companies are involved in the research, development, and commercialization of drugs to treat orphan diseases in China and around the world.

Healthcare Policies and Regulatory Landscape

The Chinese government has implemented several policies to support the development and approval of drugs to treat orphan diseases, including:

  1. Orphan Drug Designation: The Chinese Food and Drug Administration (CFDA) has established a system for granting orphan drug designation to drugs intended to treat rare diseases. This designation provides benefits such as tax incentives and expedited regulatory review.
  2. Research and Development Funding: The government provides funding for the research and development of treatments for orphan diseases through various programs and initiatives.
  3. Reimbursement Policies: The government has implemented reimbursement policies to ensure that patients have access to treatments for orphan diseases.

The CFDA is the main regulatory body responsible for the approval of drugs to treat orphan diseases in China. The agency has established a streamlined review process for orphan drugs to expedite their approval and availability to patients. The regulatory landscape for the China orphan diseases drugs market is constantly evolving, and companies must stay informed of changes to ensure compliance with regulatory requirements.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Orphan Diseases Drugs Market Segmentation

Therapeutic area

  • Cancer
  • Neurological condition
  • Cardiovascular condition
  • Musculoskeletal condition
  • Hematologic condition
  • Others

Route of administration

The injectable segment dominated the market and is expected to witness significant growth during the forecast period. This can be attributed to the launch of novel injectables for the treatment of rare diseases.

  • Oral
  • Injectable
  • Others

Drug Type

Biologics dominated the market and is expected to witness significant growth during the forecast period. The advancement in biotechnology and research techniques has facilitated the development of novel biologics. High target specificity and potential of biological drugs revolutionizing the treatments of several rare diseases are expected to fuel the segment growth.

  • Biologics
  • Biosimilars  
  • Small molecule

Distribution Channel

The specialty pharmacy segment dominated the market. The dominance can be attributed to strategic initiatives undertaken by key players, such as the acquisition of specialty pharmacies for the distribution of their products.

  • Hospital Pharmacy
  • Specialty Pharmacy
  • Online Pharmacy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 03 February 2023
Updated by: Anish Swaminathan

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up